Compare Royal Caribbean Cruises Ltd (RCL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Spyre Therapeutics Inc. Common Stock — how do they compare? Royal Caribbean Cruises Ltd trades at $276.77 (market cap $75.29B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 10× Spyre Therapeutics Inc. Common Stock's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RCL | SYRE | |
|---|---|---|
Market Cap | $75.29B | $7.52B |
Volume | 1,401,290 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $108.92 |
52-Week Low | $230.30 | $22.18 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $97.93B | $6.52B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $274.33, down 2.26% today, with a bullish technical signal and strong fundamental recovery. The stock shows robust earnings momentum with Q1 and Q2 2026 beats, while Q3 expectations are high at $6.38 EPS. Revenue growth accelerated from $8.8B in 2022 to $17.9B in 2025, with net income margins improving to 23.54%. Recent news highlights the $3B Sandals resort acquisition as a strategic expansion beyond cruising.
RCL presents a compelling growth story with analyst consensus at Buy (53% of ratings) and a $344.17 price target offering 25% upside. Key risks include execution of the Sandals integration, fuel cost volatility ($1.34B projected for 2026), and high debt levels despite improving leverage. The stock's valuation at 17.4x P/E appears reasonable given 45% ROE and positive cash flow trends.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
